Company intelligence / Profile preview

Enaiblers

Ownership: Private
Development stage: Commercial

Overview

Enaiblers has developed and commercialized an integrated AI-powered microscopy and digital pathology platform for rapid, accurate diagnosis of soil-transmitted helminths and schistosomiasis. The system enables automated whole slide imaging, offline AI analysis for parasite detection/quantification, electronic data capture/reporting, and is designed for use in low-resource settings. It is being used in monitoring & evaluation programs in partnership with public health agencies in Africa.

Therapeutic areas: Infectious Diseases
Modalities: DeviceArtificial intelligence-based diagnostic platformDigital pathology system
Industry: Pathology

Partnerships

Ministry of Health UgandaEthiopian Public Health InstituteAI4NTD Consortium

Beyond the preview

Go deeper on Enaiblers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enaiblers.

Explore the full profile